

PERSONAL INFORMATION

Maria Elisabeth Kalland

WORK EXPERIENCE

February 2015–Present

Senior scientific adviser

Norwegian Medicines Agency (Norway)

Assessment of clinical efficacy and safety of medicinal products intended for clinical trials and marketing authorization applications, within the following therapeutic fields: Oncology, diabetes, immunology and infectious diseases. Health Technology Assessments (HTA) and reimbursement decisions for hospital pharmaceuticals.

September 2014–February 2015

Nationwide Ambulatory Pharmacist

Apotek 1 Gruppen AS (Norway)

Provides pharmacies of Apotek 1 on a national level with knowledgeable and flexible pharmaceutical manpower.

September 2013–August 2014

Medical Advisor, Immunology/ Rheumatology

AbbVie AS (Norway)

Scientific/ medical expert of Humira for the treatment of patients with spondylarthritis (PsA, AS and nr-axSpA).

April 2011–September 2013

Nationwide Ambulatory Pharmacist

Apotek 1 Gruppen AS (Norway)

Provides pharmacies of Apotek 1 on a national level with knowledgeable and flexible pharmaceutical manpower.

August 2007–September 2012

Research Fellow, Molecular Medicine/ Immunology

Biotechnology Centre of Oslo, University of Oslo (Norway)

Development and systematization of protocols for carrying out basic research in the laboratory. Project management, national and international collaboration and networking. Published research results in international scientific journals and conducted supervision. Organized and held courses and lectures at scientific seminars and conferences.

January 2006–August 2007

Research assistant, Molecular Medicine/ Immunology

Biotechnology Centre of Oslo, University of Oslo (Norway)

Established new research techniques and developed protocols for these in the laboratory of my research group.

November 2004–July 2008

Pharmacist, part-time

Apotek 1 Sfinxen (Norway)

Responsible pharmacist at work. Performance of prescription dispensing that require basic knowledge of pharmacology, pharmacokinetics and drug interactions, as well as an overview of the guidelines issued by the Authority and NAV. The main focus is to provide good information to customers to ensure that medicines and pharmaceutical equipment are used optimally.

EDUCATION AND TRAINING

August 2000–December 2005

Candidatus pharmaciae (MSc.Pharm)

School of Pharmacy, University of Oslo (Norway)

Master thesis in Pharmacology, title: "Drug candidates for treatment of HIV-1 infection; characterization

of new chemical entities acting as antagonists of PKA type I in human peripheral T lymphocytes”

August 2007–September 2012

Doctor of Philosophy (Ph.D.) in Immunology

Institute of Clinical Medicine, Medical Faculty, University of Oslo (Norway)

Doctoral thesis, title: “Phosphorylation-Based Signaling in Human Immune Cells – A Systems View”:

<https://www.duo.uio.no/bitstream/handle/123456789/34491/dravhandling-kalland.pdf?sequence=2>

ADDITIONAL INFORMATION

Expertise Immunology and Oncology

Publications Størvold GL, Landskron J, Strozynski M, Arntzen MØ, Koehler CJ, Kalland ME, Taskén K, Thiede B (2013): Quantitative profiling of tyrosine phosphorylation revealed changes in the activity of the T cell receptor signaling pathway upon cisplatin-induced apoptosis. *J Proteomics.*, 91:344-57.

Kalland ME, Solheim SA, Skånland SS, Taskén K, Berge T. (2012): Modulation of proximal signaling in normal and transformed B cells by transmembrane adaptor Cbp/PAG. *Exp Cell Res.*, 318(14):1611-9.

Kalland ME, Oberprieler NG, Vang T, Taskén K, Torgersen KM. (2011): T Cell-Signaling Network Analysis Reveals Distinct Differences between CD28 and CD2 Costimulation Responses in Various Subsets and in the MAPK Pathway between Resting and Activated Regulatory T Cells. *J Immunol.*, 187(10):5233-45.

Oberprieler NG, Lemeer S, Kalland ME, Torgersen KM, Heck AJ, Taskén K. (2010): High-resolution mapping of prostaglandin E2-dependent signaling networks identifies a constitutively active PKA signaling node in CD8+CD45RO+ T cells. *Blood*, 116(13):2253-65.

Mahic M, Kalland ME, Aandahl EM, Torgersen KM, Taskén K (2008). Human naturally occurring and adaptive regulatory T cells secrete high levels of leukaemia inhibitory factor upon activation. *Scand J Immunol.*, 68(4):391-6.

Projects

Memberships

Other Relevant Information